|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
8p11 myeloproliferative syndrome preceded by t(8;9)(p11;q33), CEP110/FGFR1 fusion transcript: morphologic, molecular, and cytogenetic characterization of myeloid neoplasms associated with eosinophilia and FGFR1 abnormality.
|
18295660 |
2008 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Tumor FGFR1 phosphorylation was elevated with obesity and predicted a shorter disease-free and disease-specific survival for patients treated with tamoxifen.
|
30046001 |
2018 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Tumor-associated inflammatory microenvironment in non-small cell lung cancer: correlation with FGFR1 and TLR4 expression via PI3K/Akt pathway.
|
30854106 |
2019 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
FGFR-1 and FGFR-3 were expressed in most well-differentiated tumor types.
|
15564323 |
2005 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Fibroblast growth factor receptor 1 (FGFR1) is a receptor tyrosine kinase promoting tumor growth in a variety of cancers, including glioblastoma.
|
22903848 |
2013 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
FGFR1 knockdown mimicked the tumor suppressive effect of miR-214 on CRC cells, while reintroduction of FGFR1 abolished the tumor suppressive effect of miR-214 on CRC cells.
|
24616020 |
2014 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
FGFR1 amplification was detected in 18.5% of patients whose tumors revealed a poor response to chemotherapy, and no patients whose tumors responded well to therapy harbored this genetic alteration.
|
24861215 |
2014 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
FGFR1 is a viable therapeutic target in a subset of MPMs, but FGFR TKI-responsive tumors will need to be selected by a biomarker distinct from increased FGFR1 gene copy number, possibly FGFR1 mRNA or protein levels.
|
24966347 |
2014 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
FGFR1 amplifications (n = 5) and chromosomal aberrations (trisomy, n = 38; high polysomy, n = 30) are associated with high-grade malignancy (P < 0.001), advanced tumour size (P = 0.026) and stage (P = 0.004), gender (P = 0.016) and age (P = 0.023).
|
26661925 |
2016 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
FGFR1, FGFR2 and FGFR4 were expressed at high levels in respectively 22%, 4% and 32% of tumors.FGFR3 expression was not detected.
|
7705943 |
1995 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
A ZMYM2-FGFR1 8p11 myeloproliferative neoplasm with a novel nonsense RUNX1 mutation and tumor lysis upon imatinib treatment.
|
23751892 |
2013 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Additionally, in vivo assays revealed hsa_circRNA_103809 short hairpin RNA served as a tumor suppressor through downregulating FGFR1 in HCC.
|
31317555 |
2020 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Although FGFR-1 dimerization achieved by AIdF-2 injection led to highly differentiated and smaller NBT-II tumors, no sign of reduction of tumor angiogenesis was observed, thus suggesting that endothelial cells are resistant to FGF.
|
15273729 |
2004 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Although all tumors expressed FGFR-1 I, 1 tumor did not express FGFR-1 K, suggesting the production of only a secretable form of FGFR-1 by this tumor.
|
9100589 |
1997 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
An oncogenic fibroblast growth factor receptor 1 (FGFR1) mutation (N546K) was detected, and the FGFR1 locus frequently showed copy number gain (31.7%) in primary tumors.
|
26179511 |
2015 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Aneuploid genomes were identified in 45% of adult compared with 17% of pediatric PA. Gains were non-random, favoring chromosomes 5, 7, 6 and 11 in order of frequency, and preferentially affecting non-cerebellar PA and tumors with BRAF V600E mutations and not with KIAA1549-BRAF fusions or FGFR1 mutations.
|
26378811 |
2015 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Anti-tumor angiogenesis therapy using soluble receptors: enhanced inhibition of tumor growth when soluble fibroblast growth factor receptor-1 is used with soluble vascular endothelial growth factor receptor.
|
12136423 |
2002 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
As a consequence, genetic or pharmacological inhibition of FGFR1 in combination with trametinib enhances tumour cell death in vitro and in vivo.
|
27338794 |
2016 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
As a result, a new category, 'myeloid and lymphoid neoplasm with eosinophilia and abnormalities in PDGFRA, PDGFRB or FGFR1', has recently been added to the new WHO criteria for myeloid neoplasms.
|
20523072 |
2010 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Based on histological grading and immunohistochemical (IHC) assays, we found strong direct relationships between 80K-H and FGFR-1 (r = 0.49, p = 0.003) and tumor grade (r = 0.42, p = 0.006).
|
12841677 |
2003 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Both amplifications and deletions of RAF1 and FGFR1 were significantly associated with high tumor grade (P < 0.0001), advanced stage (P < 0.0001), and poor survival (P < 0.05) if tumors of all of the stages where analyzed together.
|
11389083 |
2001 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Both epidermal growth factor receptor (EGFR) and fibroblast growth factor receptor 1 (FGFR1) are overexpressed in the majority of human tumors, including ovarian cancer.
|
25919378 |
2015 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
By contrast, 121 cases of potential morphologic mimics (belonging to 13 tumor types) rarely expressed FGFR1, the main exceptions being solitary fibrous tumors (positive in 40%), chondroblastomas (40%), and giant cell tumors of bone (38%), suggesting a possible role for FGFR1 immunohistochemistry in the diagnosis of phosphaturic mesenchymal tumor.
|
27443518 |
2016 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
By using immunohistochemistry, we also demonstrated, for the first time, FGF receptor 1 (FGFR1) protein overexpression in this tumour, for which FN1-FGFR1 gene fusion was not detected by fluorescence in-situ hybridization.
|
26407099 |
2016 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Chronic eosinophilic leukemia not otherwise specified should be distinguished from both PDGFR-rearranged or FGFR1-rearranged neoplasms and hypereosinophilic syndrome.
|
19806146 |
2009 |